salicylaldehyde thiosemicarbazone profile

salicylaldehyde thiosemicarbazone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	135423926
CHEMBL ID	242112
SCHEMBL ID	3072985
MeSH ID	M0173045

Synonym
nsc 201642
ai3-22965
nsc 733
hydrazinecarbothioamide, 2-((2-hydroxyphenyl)methylene)-
nsc201642
nsc-201642
[(e)-(2-hydroxyphenyl)methyleneamino]thiourea
nsc733
salicylaldehyde thiosemicarbazone
salicylaldehyde, thiosemicarbazone
wln: suyzmnu1r bq
salicylic aldehyde thiosemicarbazone
nsc-733
5351-90-6
o-hydroxybenzaldehyde thiosemicarbazone
hydrazinecarbothioamide, 2-[(2-hydroxyphenyl)methylene]-
salicylaldehyde thiosemicarbazone, 95%
smr000414062
MLS000777668 ,
CHEMBL242112
2-(2-hydroxybenzylidene)hydrazinecarbothioamide
HMS1651J13
AKOS001267718
NCGC00246425-01
17149-00-7
hydrazinecarbothioamide, 2-[(2-hydroxyphenyl)methylene]-, (2e)-
(e)-2-(2-hydroxybenzylidene)hydrazinecarbothioamide
F0777-0561
AB01209855-01
SCHEMBL3072985
salicylaldehyde monothiosemicarbazone
OHNSRYBTSVDDKA-BJMVGYQFSA-N
Z49561499
salicylaldehydthiosemicarbazon
salicyaldehyde thiosemicarbazone
salicylaldehyde thiosemicarbazone 95
CS-0112105
[(e)-(2-hydroxyphenyl)methylideneamino]thiourea
2-(2-hydroxybenzylidene)hydrazine-1-carbothioamide

Protein Targets (16)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	89.1251	0.6310	35.7641	100.0000	AID504339
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	28.1838	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	19.9526	5.6234	17.2929	31.6228	AID485281
acid sphingomyelinase	Homo sapiens (human)	Potency	31.6228	14.1254	24.0613	39.8107	AID504937
glp-1 receptor, partial	Homo sapiens (human)	Potency	7.9433	0.0184	6.8060	14.1254	AID624417
GLS protein	Homo sapiens (human)	Potency	25.1189	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	4.8288	0.0008	11.3822	44.6684	AID686978; AID686979
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	35.4813	0.7079	36.9043	89.1251	AID504333
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	31.6228	0.0366	19.6376	50.1187	AID2100
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	112.2020	5.8048	36.1306	65.1308	AID540263
snurportin-1	Homo sapiens (human)	Potency	112.2020	5.8048	36.1306	65.1308	AID540263
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	4.9288	0.0079	8.2332	1,122.0200	AID2546; AID2551
lethal(3)malignant brain tumor-like protein 1 isoform I	Homo sapiens (human)	Potency	19.9526	0.0752	15.2253	39.8107	AID485360
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	0.8913	4.4668	8.3448	10.0000	AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
nonstructural protein 1	Influenza A virus (A/California/07/2009(H1N1))	IC50 (µMol)	14.1110	0.2000	24.4540	100.0000	AID504329
Polyphenol oxidase 2	Agaricus bisporus	IC50 (µMol)	0.3800	0.0340	3.9871	10.0000	AID1571721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Process	via Protein(s)	Taxonomy
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Process	via Protein(s)	Taxonomy
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1381688	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form assessed as parasite growth inhibition at 50 uM after 72 hrs by SYBR Green assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381706	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381729	Inhibition of Leishmania major PTR1 at 50 uM using H2B as substrate in presence of NADPH by photometric analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID527289	Inhibition of melanogenesis in mouse B16 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Structural characteristics of thiosemicarbazones as inhibitors of melanogenesis.
AID1381694	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381689	Antileishmanial activity against Leishmania infantum amastigote form assessed as parasite growth inhibition at 50 uM after 72 hrs by steady-Glo reagent based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381710	Cytotoxicity against human 786-O cells assessed as inhibition of mitochondrial viability at 10 uM after 6 hrs by CMXRos staining based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID382091	Antiproliferative activity against human Hep2 cells after 72 hrs by MTT test	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID1381709	Cytotoxicity against human WI38 cells assessed as growth inhibition at 10 uM after 48 hrs by CellTiter-Glo assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381703	Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381728	Inhibition of Trypanosoma brucei PTR1 at 50 uM using H2B as substrate in presence of NADPH by photometric analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381697	Potentiation of methotrexate-induced antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID382093	Antiproliferative activity against human MiaPaCa2 cells after 72 hrs by MTT test	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID382096	Antiproliferative activity against human WI38 cells after 72 hrs by MTT test	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID382094	Antiproliferative activity against human SW620 cells after 72 hrs by MTT test	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID1381705	Inhibition of human microsomal CYP2D6 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381702	Inhibition of human ERG at 10 uM incubated for 2 hrs by fluorescence polarisation assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381704	Inhibition of human microsomal CYP2C19 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID382095	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT test	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID1381690	Antitrypanosomal activity against Trypanosoma cruzi amastigote form infected in human U2OS cells assessed as parasite growth inhibition at 50 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID293934	Inhibition of pieris rapae Phenoloxidase	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
AID1381696	Inhibition of human microsomal CYP1A2 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID382090	Binding affinity to calf thymus DNA in aqueous solution at pH 7.0 by thermal denaturation	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID1571721	Inhibition of mushroom tyrosinase using L-dopa as substrate preincubated for 10 mins followed by substrate addition and measured for 1 min	2019	MedChemComm, Mar-01, Volume: 10, Issue:3	Thiosemicarbazones with tyrosinase inhibitory activity.
AID527288	Inhibition of melanogenesis in mouse B16 cells at 10 uM	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Structural characteristics of thiosemicarbazones as inhibitors of melanogenesis.
AID1381708	Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by CellTiter-Glo assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381712	Cytotoxicity against human U2OS cells assessed as viable cells at 50 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID382092	Antiproliferative activity against human HeLa cells after 72 hrs by MTT test	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
AID1381707	Inhibition of recombinant full-length human aurora B kinase expressed in baculovirus system at 10 uM using MBP as substrate incubated for 45 mins by ADP-glo kinase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381711	Cytotoxicity against human THP1 cells assessed as viable cells at 100 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381695	Potentiation of methotrexate-induced antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381691	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form after 72 hrs by SYBR Green assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (4.76)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (28.57)	29.6817
2010's	11 (52.38)	24.3611
2020's	3 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.76%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (95.24%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
protocatechuic acid protocatechuic acid: RN given refers to parent cpd; structure. 3,4-dihydroxybenzoic acid : A dihydroxybenzoic acid in which the hydroxy groups are located at positions 3 and 4.	2.03	1	catechols; dihydroxybenzoic acid	antineoplastic agent; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; human xenobiotic metabolite; plant metabolite
3-hydroxybenzaldehyde [no description available]	2.03	1	hydroxybenzaldehyde
4-hydroxybenzaldehyde [no description available]	2.03	1	hydroxybenzaldehyde	EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor; mouse metabolite; plant metabolite
4-hydroxybenzoic acid 4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.	2.03	1	monohydroxybenzoic acid	algal metabolite; plant metabolite
benzaldehyde [no description available]	2.03	1	benzaldehydes	EC 3.1.1.3 (triacylglycerol lipase) inhibitor; EC 3.5.5.1 (nitrilase) inhibitor; flavouring agent; fragrance; odorant receptor agonist; plant metabolite
benzoic acid Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.	2.03	1	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
cuminaldehyde cuminaldehyde : A member of the class of benzaldehydes that is benzaldehyde substituted by an isopropyl group at position 4. It is a component of essential oils from Cumin and exhibits insecticidal activities.	2.03	1	benzaldehydes	insecticide; plant metabolite; volatile oil component
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2.03	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	2.04	1	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.07	1	metal allergen; nickel group element atom	epitope; micronutrient
vanillin Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).	2.03	1	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
beta-resorcylic acid beta-resorcylic acid: RN given refers to parent cpd; structure	2.03	1
2,5-dihydroxybenzoic acid 2,5-dihydroxybenzoic acid: RN given refers to parent cpd; a oxidative product of saligenin. 2,5-dihydroxybenzoic acid : A dihydroxybenzoic acid having the two hydroxy groups at the 2- and 5-positions.	2.03	1	dihydroxybenzoic acid	EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; fungal metabolite; human metabolite; MALDI matrix material; mouse metabolite
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.17	1	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
kojic acid [no description available]	3.31	1	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.17	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
salicylaldehyde o-hydroxybenzaldehyde: structure in first source	2.03	1	hydroxybenzaldehyde	nematicide; plant metabolite
2,4-dihydroxybenzaldehyde 2,4-dihydroxybenzaldehyde : A dihydroxybenzaldehyde that is resorcinol which has been substituted by a formyl group para to one of the hydroxy groups.	2.03	1	dihydroxybenzaldehyde
4-tert-butylbenzoic acid 4-tert-butylbenzoic acid: RN given refers to parent cpd	2.03	1	alkylbenzene
3-hydroxybenzoic acid 3-hydroxybenzoic acid: RN given refers to parent cpd. 3-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid substituted by a hydroxy group at position 3. It has been isolated from Taxus baccata. It is used as an intermediate in the synthesis of plasticisers, resins, pharmaceuticals, etc.	2.03	1	monohydroxybenzoic acid	bacterial metabolite; plant metabolite
4-anisic acid 4-methoxybenzoic acid: structure in first source. 4-methoxybenzoic acid : A methoxybenzoic acid substituted with a methoxy group at position C-4.	2.03	1	methoxybenzoic acid	plant metabolite
vanillic acid Vanillic Acid: A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).. vanillic acid : A monohydroxybenzoic acid that is 4-hydroxybenzoic acid substituted by a methoxy group at position 3.	2.03	1	methoxybenzoic acid; monohydroxybenzoic acid	plant metabolite
2-Methoxybenzaldehyde [no description available]	2.03	1	carbonyl compound
protocatechualdehyde protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure	2.03	1	dihydroxybenzaldehyde
2-vanillin ortho-vanillin : A member of the class of benzaldehydes that is salicylaldehyde substituted by a methoxy group at position 3.	2.03	1	benzaldehydes; guaiacols	antimutagen; plant metabolite
cumic acid cumic acid : A member of the class of benzoic acids that is cumene substituted by at least one carboxy group.. p-cumic acid : A cumic acid that consists of benzoic acid substituted by an isopropyl group at position 4.	2.03	1	cumic acid	plant metabolite
3-methoxybenzoic acid [no description available]	2.03	1	methoxybenzoic acid	flavouring agent; human urinary metabolite
3-methoxybenzaldehyde 3-methoxybenzaldehyde : A member of the class of benzaldehydes in which the hydrogen at position 3 of benzaldehyde has been replaced by a methoxy group.	2.03	1	benzaldehydes; monomethoxybenzene	Brassica napus metabolite
triphenylphosphine triphenylphosphine: RN given refers to parent cpd. triphenylphosphine : A member of the class of tertiary phosphines that is phosphane in which the three hydrogens are replaced by phenyl groups.	2.06	1	benzenes; tertiary phosphine	NMR chemical shift reference compound; reducing agent
isovanillin isovanillin: inhibits aldehyde oxidase. isovanillin : A member of the class of benzaldehydes that is 4-methoxybenzaldehyde substituted by a hydroxy group at position 3. It is an inhibitor of aldehyde oxidase.	2.03	1	benzaldehydes; monomethoxybenzene; phenols	animal metabolite; antidiarrhoeal drug; antifungal agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; HIV protease inhibitor; plant metabolite
isovanillic acid 3-hydroxy-4-methoxybenzoic acid : A methoxybenzoic acid that is 4-methoxybenzoic acid bearing a hydroxy substituent at position 3.	2.03	1	methoxybenzoic acid; monohydroxybenzoic acid	antibacterial agent; plant metabolite
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.07	1	metal allergen; nickel group element atom; platinum group metal atom
ruthenium Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.	2.06	1	iron group element atom; platinum group metal atom
vanadium Vanadium: A metallic element with the atomic symbol V, atomic number 23, and atomic weight 50.94. It is used in the manufacture of vanadium steel. Prolonged exposure can lead to chronic intoxication caused by absorption usually via the lungs.	2.02	1	elemental vanadium; vanadium group element atom	micronutrient
4-anisaldehyde 4-anisaldehyde: RN given refers to cpd with specified locants for methoxy moieties; structure in Merck, 9th ed, #696. p-methoxybenzaldehyde : A member of the class of benzaldehydes consisting of benzaldehyde itself carrying a methoxy substituent at position 4.	2.03	1	benzaldehydes	bacterial metabolite; human urinary metabolite; insect repellent; plant metabolite
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.17	1	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
3-amino-4-hydroxybenzoic acid 3-amino-4-hydroxybenzoic acid : A monohydroxybenzoic acid that is 4-hydroxybenzoic acid carrying an additional amino substitutent at position 3.	2.03	1	aminobenzoic acid; monohydroxybenzoic acid
2-hydroxy-4-methoxybenzaldehyde 2-hydroxy-4-methoxybenzaldehyde: from African medicinal plants: Mondia whitei (Apocynaceae), Rhus vulagaris (Anacardiaceae), Sclerocarya caffra (Anacardiaceae)	2.03	1	methoxybenzenes; phenols
2,5-dihydroxybenzaldehyde 2,5-dihydroxybenzaldehyde: structure in first source. 2,5-dihydroxybenzaldehyde : A dihydroxybenzaldehyde carrying hydroxy groups at positions 2 and 5.	2.03	1	dihydroxybenzaldehyde	human metabolite; mouse metabolite; Penicillium metabolite
methotrexate [no description available]	2.17	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
4-amino-3-hydroxybenzoic acid [no description available]	2.03	1
4-propylbenzoic acid [no description available]	2.03	1	alkylbenzene
2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole: structure in first source	2.17	1
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.07	1
mtt formazan MTT formazan: a blue MEM-insoluble mitochondrial byproduct; used to determine viability of cells with active mitochondrial dehydrogenase enzymes	2.06	1
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.17	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
2-formylpyridine thiosemicarbazone 2-formylpyridine thiosemicarbazone: structure; RN given refers to parent cpd without isomeric designation	2.05	1
4-isopropylbenzaldehyde thiosemicarbazone 4-isopropylbenzaldehyde thiosemicarbazone: structure in first source	2.03	1
3-hydroxy-4-methoxybenzaldehyde thiosemicarbazone 3-hydroxy-4-methoxybenzaldehyde thiosemicarbazone: inhibits cabbage butterfly larvae phenoloxidase; structure in first source	3.59	2
cinnamaldehyde thiosemicarbazone cinnamaldehyde thiosemicarbazone: has antimicrobial activity; structure in first source	3.69	2
formazans Formazans: Colored azo compounds formed by the reduction of tetrazolium salts. Employing this reaction, oxidoreductase activity can be determined quantitatively in tissue sections by allowing the enzymes to act on their specific substrates in the presence of tetrazolium salts.	2.06	1

Condition	Relationship Strength	Studies
B16 Melanoma [description not available]	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
American Trypanosomiasis [description not available]	2.17	1
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	2.17	1
Cancer of Kidney [description not available]	2.02	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.02	1

salicylaldehyde thiosemicarbazone

Description

Cross-References

Synonyms (39)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Biological Processes (14)

Molecular Functions (3)

Ceullar Components (5)

Bioassays (47)

Research

Studies (21)

Study Types

salicylaldehyde thiosemicarbazone

Description

Cross-References

Synonyms (39)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Biological Processes (14)

Molecular Functions (3)

Ceullar Components (5)

Bioassays (47)

Research

Studies (21)

Study Types

Related Drugs (51)

Related Conditions (9)